TXG Aug 2024 15.000 put
| Previous close | 1.0000 |
| Open | 0.7300 |
| Bid | 0.1000 |
| Ask | 1.1500 |
| Strike | 15.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.7300 - 0.7300 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
PR NewswireNew Insights Into Cleft Palate Unlocked With 10x Genomics' Single Cell and Spatial Technologies
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate. The study was led by researchers at the National Institutes of Health (NIH) in collaboration with computational experts at the University of Connecticut's Schools of Medicine and Dental Medicine.
Insider MonkeyDoes 10x Genomics (TXG) Have a Strong Growth Opportunity Ahead?
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The Small Company Fund returned 0.48%, significantly underperforming the Russell 2000 Growth index’s 7.58% return. Following the release of the inflation report in February, the […]
- PR Newswire
10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel. The new panel features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation and industry-leading speed and throughput.
